research New-onset systemic lupus erythematosus beginning as class V lupus nephritis after COVID-19 vaccination
COVID-19 vaccination may trigger lupus in some people.
Search
for
Sort by
Research
660-690 / 1000+ results
research What does androgenetic alopecia have to do with COVID‐19? An insight into a potential new therapy
Androgenetic alopecia linked to COVID-19 severity; drugs reducing androgen receptor activation may help.
research Telogen effluvium associated with COVID‐19 infection
COVID-19 may cause hair loss due to infection stress or treatments.
research Teledermatology in the COVID-19 pandemic: A systematic review
Teledermatology became a valuable and convenient tool for skin care during the COVID-19 pandemic.
research Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management
COVID-19 patients often experience hair loss and scalp pain, which may be related to the severity of their infection and treatment drugs.
research COVID‐19 and dermatology: a comprehensive guide for dermatologists
Dermatologists should watch for skin symptoms in COVID-19 patients, prioritize urgent cases, and use telemedicine.
research Recurrence of cutaneous T‐cell lymphoma post viral vector COVID‐19 vaccination
COVID-19 vaccination may trigger recurrence of cutaneous T-cell lymphoma in some patients.
research Time of onset and duration of post-COVID-19 acute telogen effluvium
Hair loss from COVID-19 usually starts around 45 days after infection and lasts about 47.5 days.
research Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign
AGA linked to worse COVID-19 outcomes in men.
research The Double Edge Sword of Testosterone’s Role in the COVID-19 Pandemic
Testosterone may influence COVID-19 severity and outcomes.
research Clinical symptoms of hyperandrogenic women diagnosed with COVID‐19
Women with high androgen levels may have more severe COVID-19 symptoms.
research Male balding is a major risk factor for severe COVID-19
Men with severe balding have a higher risk of getting very sick from COVID-19.
research Alopecia and grey hair are associated with COVID‐19 Severity
Having a lot of gray hair and hair loss are linked to more severe COVID-19.
research Hormonal trends in patients suffering from long COVID symptoms
Long COVID patients may have hormonal imbalances linked to their symptoms.
research A systematic review of acute telogen effluvium, a harrowing post‐COVID‐19 manifestation
COVID-19 can cause a type of hair loss that usually starts 74 days after infection, affecting mostly women, but most patients eventually recover.
research COVID-19 infection is a major cause of acute telogen effluvium
COVID-19 infection can significantly cause temporary hair loss.
research Dermatological manifestations associated with COVID‐19: A comprehensive review of the current knowledge
COVID-19 can cause various skin issues, including rashes and hair loss, which usually heal on their own and don't always indicate severe illness.
research An Ecologic Study of Disparities in COVID-19 Incidence and Case Fatality in Oakland County, MI, USA, During a State-Mandated Shutdown
COVID-19 affected Black communities more in Oakland County, MI, but didn't increase death rates.
research Italian Survey for the Evaluation of the Effects of Coronavirus Disease 2019 (COVID-19) Pandemic on Alopecia Areata Recurrence
COVID-19 increased alopecia areata relapses due to inflammation and stress.
research A concomitant diagnosis of COVID‐19 infection and systemic lupus erythematosus complicated by a macrophage activation syndrome: A new case report
COVID-19 may trigger systemic lupus erythematosus, requiring careful diagnosis and treatment.
research Relationship between betacoronaviruses and the endocrine system: a new key to understand the COVID-19 pandemic—A comprehensive review
Betacoronaviruses, like COVID-19, may cause hormone system dysfunction and affect disease susceptibility and severity.
research Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review
COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.
research Epidemiology of post-COVID conditions beyond 1 year: a cross-sectional study
Over 25% of COVID-19 patients had symptoms lasting more than a year.
research Are sex hormones promising candidates to explain sex disparities in the COVID-19 pandemic?
Sex hormones like estrogen and testosterone may affect COVID-19 severity differently in men and women, potentially influencing prevention and treatment strategies.
research COVID-19-Related Neuropathic Pain: A Systematic Review and Meta-Analysis
Neuropathic pain is common in long COVID patients, especially those with depression or severe COVID-19.
research Pathobiology questions raised by telogen effluvium and trichodynia in COVID‐19 patients
COVID-19 may cause hair loss and scalp pain due to inflammation and changes in hair follicle receptors, but these symptoms typically resolve in 2 to 4 months.
research COVID-19 clinical outcomes and nationality: results from a Nationwide registry in Kuwait
Non-Kuwaiti COVID-19 patients had worse health outcomes than Kuwaitis, likely due to poorer socioeconomic conditions.
research COVID-19 and andrology: Recommendations of the French-speaking society of andrology (Société d’Andrologie de langue Française SALF)
Wait 3 months after COVID-19 before trying assisted reproduction and further research is needed on COVID-19's effects on male hormones and fertility.
research Safety and efficacy of the COVID-19 vaccine in children and/or adolescents:A meta-analysis
COVID-19 vaccines are safe and highly effective for children, with inactivated vaccines being slightly better.
research COVID-19 and hypopituitarism
COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.